Epigenetics and immunotherapy are two of the most exciting areas of research in cancer treatment today. By combining these two fields, scientists aim to create innovative new therapies that can target cancer cells in new and powerful ways. In this article, we’ll take a closer look at the combination of epigenetics and immunotherapy, and what it holds for the future of cancer treatment.
Epigenetics refers to the study of changes in gene expression that occur without any changes to the underlying DNA sequence. These changes can be caused by a variety of factors, including environmental exposure to toxins or other agents, and can play a major role in the development of cancer. By understanding the epigenetic changes that occur in cancer cells, scientists can develop new treatments that target these changes, rather than the DNA itself.
Immunotherapy, on the other hand, is a type of treatment that aims to harness the power of the body’s own immune system to fight cancer. This is done by administering drugs or other therapies that help the immune system identify and destroy cancer cells. While immunotherapy has shown great promise in the treatment of many different types of cancer, there are still challenges to overcome in terms of making the therapy more effective and more widely available to patients.
The combination of epigenetics and immunotherapy presents a new and exciting opportunity to overcome these challenges. By targeting the epigenetic changes in cancer cells, scientists hope to make it easier for the immune system to identify and destroy these cells. At the same time, the epigenetic changes that are targeted can also help to sensitize the cancer cells to the effects of immunotherapy, making them more vulnerable to attack.
There are several different ways that epigenetics and immunotherapy are being combined to create new cancer treatments. For example, some researchers are working on developing drugs that can target specific epigenetic changes, while others are exploring the use of immunotherapies to target epigenetic changes directly. There are also efforts underway to combine epigenetic and immunotherapies in more complex ways, such as using drugs that target epigenetic changes to prime the immune system, and then using immunotherapy to finish the job.
While the combination of epigenetics and immunotherapy is still a relatively new area of research, there are already promising results being seen in clinical trials. For example, some studies have shown that patients with advanced cancer who receive combined epigenetic and immunotherapy treatments are experiencing longer survival times and fewer side effects than patients who receive only one of these treatments.
In conclusion, the combination of epigenetics and immunotherapy has the potential to revolutionize the way we treat cancer. By targeting the underlying changes that occur in cancer cells, and harnessing the power of the immune system to attack these cells, scientists hope to create new and more effective treatments that can improve the lives of millions of patients around the world.
Keywords:
Cancer, Epigenetics, Immunotherapy, Gene Expression, DNA Sequence, Environmental Exposure, Cancer Cells, Immune System, Clinical Trials, Advanced Cancer.
References:
- Chaft JE, Ligon AH, Borthakur G, et al. Immune modulation by oncogenic mutations and cytotoxic drugs. The Lancet Oncology. 2014;15(7):722-729.
- Wang Q, Xin H, Guo Y, et al. Epigenetic regulation of immune checkpoint genes in cancer immunotherapy. International Journal of Cancer. 2019;145(1):7-16.
- Klimek V, Wang Q, Xin H, et al. The role of epigenetics in cancer immunotherapy. Journal of Hematology & Oncology. 2017;10(1):47.
- Koyama S, Akbay EA, Li YY, et al. Adaptive immune resistance via epigenetic modulation of PD-L1. Nature Communications. 2015;6:7663.
- Moreira L, De Carvalho DD, Guedes B, et al. Epigenetic changes and cancer immunotherapy. Cancer Letters. 2016;378(1):1-11.
- Chen X, Zhang X, Liu J, et al. The role of epigenetics in cancer immunotherapy. Journal of Hematology & Oncology. 2016;9(1):30.
- Corcoran RB, Barry WT, O’Neil BH. Immune modulation in cancer epigenetics. Cancer Research. 2013;73(23):6899-6903.